Suneet Purohit, MD
Cardiovascular Disease · Anchorage, AKNPI 1760781553
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,950 of the $76,948 with a category attached, or 67.5%. 22 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 51.8% of the total. 2025 is the largest year on record at $49,755, more than ten times the $1,721 reported in 2019. Among cardiovascular disease clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $343.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$40K
- Bridgebio Pharma, Inc.$29K
- Kiniksa Pharmaceuticals, Ltd.$2K
- Abbott$2K
- Novartis$720
- Alnylam Pharmaceuticals Inc.$560
- plus $2K from 16 others
Across 1 payment — averaging $187.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$187
What the payments were for
- Consulting fees$10,70014%
- Speaking & faculty fees$51,95068%
- Travel & lodging$7,2319%
- Food & beverage$7,0479%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 84 | $39,868 |
| Bridgebio Pharma, Inc. | 25 | $29,242 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $2,455 |
| Abbott | 28 | $2,242 |
| Novartis | 31 | $720 |
| Alnylam Pharmaceuticals Inc. | 13 | $560 |
| Impulse Dynamics (USA) Inc. | 3 | $420 |
| Pfizer | 11 | $311 |
| Bayer | 1 | $200 |
| Actelion Pharmaceuticals US, Inc. | 3 | $196 |
| United Therapeutics Corporation | 3 | $145 |
| Abiomed | 1 | $125 |
| Amgen | 5 | $96 |
| Lilly USA, LLC | 1 | $82 |
| AstraZeneca | 2 | $81 |
| Merck | 3 | $64 |
| Boehringer Ingelheim | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Heron Therapeutics, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$30,263
- Attruby$29,029
- ARCALYST$2,400
- HeartMate PHP$1,051
- OPTIMIZER$839
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$251
- Adempas$200
- Impella$125
- ONPATTRO$122
- AMVUTTRA$118
- UPTRAVI$113
- OPSUMIT$113
- HeartMate 3 Left Ventricular Dev$112
How this compares
$76,948 in reported general payments places this provider in the 95th percentile of 26 cardiovascular disease providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 66 | $2,184,203 |
| EntrestoSacubitril/Valsartan | 475 | $643,051 |
| JardianceEmpagliflozin | 374 | $475,918 |
| VyndaqelTafamidis Meglumine | 17 | $393,235 |
| EliquisApixaban | 312 | $379,933 |
| FarxigaDapagliflozin Propanediol | 73 | $94,399 |
| XareltoRivaroxaban | 77 | $88,418 |
| Ambrisentan | 12 | $79,965 |
| Repatha SureclickEvolocumab | 34 | $39,597 |
| NexletolBempedoic Acid | 18 | $20,805 |
| Metoprolol Succinate | 432 | $7,460 |
| Eplerenone | 72 | $6,344 |
| Spironolactone | 554 | $5,338 |
| Torsemide | 139 | $5,068 |
| Rosuvastatin Calcium | 271 | $4,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $311 | $2,957,370395 claims |
| NovartisEntresto | $720 | $643,051475 claims |
| Boehringer IngelheimJardiance | $40 | $475,918374 claims |
| AstraZenecaFarxiga | $81 | $94,39973 claims |
| Johnson & JohnsonXarelto | $17 | $88,41877 claims |
| Esperion Therapeutics, Inc.Nexletol | $18 | $20,80518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 cardiovascular disease providers in Alaska.
Other cardiovascular disease in Anchorage
- Ahmed AbuzaidAnchorage$77K
- Jeffrey DixsonAnchorage$2K
- Brian ScullyAnchorage$2K
- Mario BinderAnchorage$2K
- Hung VoAnchorage$1K
- William MayerAnchorage$1K
- Moyukh GhoshAnchorage$1K
- Leo BustadAnchorage$818
- Scott EbenhoehAnchorage$658
- Linda IrelandAnchorage$415
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.